VERONA PHARMA P/S (NASDAQ:VRNA) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Wednesday.
Several other brokerages have also weighed in on VRNA. Jefferies Financial Group reissued a “buy” rating and set a $26.00 price objective on shares of VERONA PHARMA P/S in a report on Friday, August 10th. Wedbush set a $56.00 price objective on VERONA PHARMA P/S and gave the company a “buy” rating in a report on Tuesday, August 7th. Finally, Zacks Investment Research raised VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a report on Friday, August 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. VERONA PHARMA P/S currently has a consensus rating of “Buy” and a consensus price target of $31.33.
Shares of NASDAQ VRNA opened at $10.90 on Wednesday. VERONA PHARMA P/S has a 1-year low of $10.19 and a 1-year high of $25.55. The firm has a market cap of $153.16 million, a price-to-earnings ratio of -4.52 and a beta of -1.37.
An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Foresite Capital Management IV LLC purchased a new position in VERONA PHARMA P/S (NASDAQ:VRNA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 8,302 shares of the company’s stock, valued at approximately $104,000. VERONA PHARMA P/S accounts for approximately 0.0% of Foresite Capital Management IV LLC’s portfolio, making the stock its 21st largest position. Foresite Capital Management IV LLC owned approximately 0.06% of VERONA PHARMA P/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 56.23% of the company’s stock.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Featured Article: How to calculate the annual rate of depreciation
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.